Relentlessly identifying every action possible to help reduce the patients’ wait for your therapy.

With Heart

Our 1000+ strong consulting team includes ~100 former regulators/HTA assessors, alongside industry luminaries, who know exactly how to help you navigate regulatory and access hurdles to reach patients sooner.

Tell me more

Four strategies for oncology drug development in a post-COVID world

COVID-19 has changed every aspect of drug development. From novel endpoints to the advanced adoption of real-world evidence to decentralized trial designs, Parexel's experts and one insightful patient explore what new imperatives oncology drug developers can adopt to speed life-changing therapies to patients in need.

  • Incorporating novel surrogate endpoints
  • Leveraging external / synthetic control arms
  • Patient insights for oncology trial design
  • Benefits of demonstrating value earlier

Passionately guiding you through a regulatory and access environment they helped shape.


"With unrivaled real-world experience and a collective resume unlike any other team in the industry, our elite group can help you identify and navigate the requirements of regulators, providers, payers and patients holistically, and early. So you can get your innovation from the lab to the people who need it most, faster – with heart."

Paul Bridges
Senior Vice President and Worldwide Head of Regulatory & Access, Parexel 


Unrivaled real-world expertise includes:

  • 1000+ strong consulting team with ~100 former regulators and HTA assessors
  • Localized knowledge covering 110 countries
  • Therapeutic experts with deep technical expertise
  • Market access specialists with proven health technology assessment (HTA) success

View their profiles

Learn more about Parexel Regulatory & Access Consulting services